Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

This study is testing a highly focused, short-course radiation treatment (called stereotactic body radiotherapy or SBRT) for men with prostate cancer whose PSA level has risen after having their prostate surgically removed. **You may be eligible if:** - You previously had your prostate removed for prostate cancer - Your PSA has been rising on two or more consecutive blood tests (above 0.03 ng/mL), OR you had high-risk features found during surgery, OR your cancer spread to nearby lymph nodes - You are 18 or older and in reasonably good physical health - You had recent pelvic imaging (CT and MRI within the last 4 months) **You may NOT be eligible if:** - There is evidence that your cancer has spread to distant parts of the body - You have a rare type of prostate cancer (neuroendocrine or small cell) - You have already received radiation to the pelvis - You have Crohn's disease, ulcerative colitis, or ataxia telangiectasia (a rare genetic disorder) Talk to your doctor to see if this trial is right for you.